Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 211

Sort by

Sort Order Select

Journal Articles

Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma

Blood blood.2024024995.

https://doi.org/10.1182/blood.2024024995

Published: 2024

Includes: Supplemental data

Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Blood (2023) 142 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2023-191911

Published: 2023

Journal Articles

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Blood (2023) 142 (18): 1518–1528.

https://doi.org/10.1182/blood.2022019531

Published: 2023

Journal Articles

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Blood (2023) 142 (10): 865–877.

https://doi.org/10.1182/blood.2023020578

Published: 2023

Includes: Supplemental data

Journal Articles

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 2101–2103.

https://doi.org/10.1182/blood-2022-167247

Published: 2022

Journal Articles

Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2022) 140 (Supplement 1): 378–380.

https://doi.org/10.1182/blood-2022-169219

Published: 2022

Journal Articles

Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT

Anna Sureda, Ariane Boumendil, Philipp Berning, Hervé Finel, Denis Caillot, Wolf Roesler, Jürgen Finke, Igor Wolfgang Blau, Veronique Leblond, Joerg Bittenbring, Anna Tsoulkani, Ben Carpenter, Arnon Nagler, Didier Blaise, Peter Dreger, Norbert Schmitz

Blood (2022) 140 (Supplement 1): 10606–10607.

https://doi.org/10.1182/blood-2022-169737

Published: 2022

Journal Articles

Real-Life Experience of Use of Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia. a Single Center Experience

Helena Pomares, Villarreal Hernandez Jasson, Susana Vives, Marta Cervera, Rosa Coll, Lurdes Zamora, Clara Maluquer, Gladys Ibarra, Julia Ribes Amoros, Georgina Gener-Ricós, Mercedes Galiano, Anna Sureda, Montserrat Arnan Sangerman

Blood (2022) 140 (Supplement 1): 9021–9022.

https://doi.org/10.1182/blood-2022-168819

Published: 2022

Journal Articles

International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation

Blood (2022) 140 (Supplement 1): 5225–5227.

https://doi.org/10.1182/blood-2022-165010

Published: 2022

Journal Articles

Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Blood (2022) 140 (Supplement 1): 10413–10415.

https://doi.org/10.1182/blood-2022-169037

Published: 2022

Journal Articles

Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study

Blood (2022) 140 (Supplement 1): 7734–7737.

https://doi.org/10.1182/blood-2022-168601

Published: 2022

Journal Articles

An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Molly Tokaz, Helen Baldomero, Andrew J Cowan, Wael Saber, Hildegard T. Greinix, Mickey Koh, Nicolaus Kröger, Mohamad Mohty, Sebastian Galeano, Shinichiro Okamoto, Naeem A. Chaudhri, Amado J Karduss, Fabio Ciceri, Vergilio Rensi Colturato, Selim Corbacioglu, Alaa M. Elhaddad, Lisa Force, Cristobal Augusto Frutos Ortiz, Andres Gomez-De Leon, Nada Hamad, Nelson Hamerschlak, Naya He, Aloysius YL Ho, Xiao-Jun Huang, Benjamin Jacobs, Heeje Kim, Minako Iida, Leslie E. Lehmann, Régis Peffault de Latour, Mary-Elizabeth M. Percival, Walid Rasheed, Kirk R. Schultz, Adriana Seber, Bor-Sheng Ko, Anderson Simione, Alok Srivastava, Jeff Szer, William A. Wood, Yoshihisa Kodera, Arnon Nagler, John A Snowden, Daniel J. Weisdorf, Jakob R. Passweg, Marcelo C Pasquini, Anna Sureda, Yoshiko Atsuta, Mahmoud Aljurf, Dietger Niederwieser, Martina Perdomo

Blood (2022) 140 (Supplement 1): 8146–8149.

https://doi.org/10.1182/blood-2022-158338

Published: 2022

Journal Articles

Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2022) 140 (Supplement 1): 6558–6560.

https://doi.org/10.1182/blood-2022-167644

Published: 2022

Journal Articles

Orthotopic Xenografts Models in Relapse/Refractory Lymphomas: A Preclinical Model for Therapeutic, Mechanistic and Functional Studies

Domingo Domenech Eva, Fina Climent, Eva Gonzalez Barca, Eugenia de Lama, Maria Martinez Iniesta, Monica Calaf, Clara Montane, Ana C Oliveira, Patricia Lopez, Gabriela Sanz-Linares, Esmeralda de la Banda, Laura Arregui, Villanueva Alberto, Anna Sureda, Lourdes Farre

Blood (2022) 140 (Supplement 1): 8829–8830.

https://doi.org/10.1182/blood-2022-164848

Published: 2022

Journal Articles

Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial

Blood (2022) 140 (Supplement 1): 2098–2100.

https://doi.org/10.1182/blood-2022-165441

Published: 2022

Journal Articles

Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow

Blood (2022) 140 (Supplement 1): 2095–2097.

https://doi.org/10.1182/blood-2022-167382

Published: 2022

Journal Articles

Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study

Blood (2022) 140 (Supplement 1): 1849–1851.

https://doi.org/10.1182/blood-2022-166329

Published: 2022

Journal Articles

A Spanish Medical Record Review of Adults with Relapsed or Refractory CD30+ Malignancies When Re-Treated with Brentuximab Vedotin (BV): Preliminary Analysis of the Believe Study (NCT:04998331)

Anna Sureda, Lourdes Baeza, Andrea Naves, Jesús Aparicio, Ramón García-Sanz

Blood (2022) 140 (Supplement 1): 12116–12118.

https://doi.org/10.1182/blood-2022-163043

Published: 2022

Journal Articles

Prospective Assessment of Motor Neurotoxicity and Sarcopenia in CD30+ Lymphoma Patients Treated with Brentuximab Vedotin. Single Center Multidisciplinary Unit Experience

Domingo Domenech Eva, Marta Bellver, German Ferrer, Eva Gonzalez Barca, Itziar Carro, Ana C Oliveira, Patricia Lopez, Gabriela Sanz-Linares, Carmen Aguilera, Montserrat Alemany, Inmaculada Peiro, Anna Sureda, Roser Velasco

Blood (2022) 140 (Supplement 1): 9420–9421.

https://doi.org/10.1182/blood-2022-165345

Published: 2022

Journal Articles

Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Ranjana H. Advani, Abraham Avigdor, Anna Sureda, David Lavie, Stefan Hohaus, Jan M. Zaucha, Vu Minh Hua, Vittorio Ruggero Zilioli, Raimundo Gazitua, Muhit Özcan, Amos Odeleye-Ajakaye, Uzor C. Ogbu, Akash Nahar, Jane N. Winter

Blood (2022) 140 (Supplement 1): 1759–1760.

https://doi.org/10.1182/blood-2022-163787

Published: 2022

NARROW

Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT

Real-Life Experience of Use of Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia. a Single Center Experience

International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation

Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study

An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

Orthotopic Xenografts Models in Relapse/Refractory Lymphomas: A Preclinical Model for Therapeutic, Mechanistic and Functional Studies

Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial

Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow

Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study

A Spanish Medical Record Review of Adults with Relapsed or Refractory CD30+ Malignancies When Re-Treated with Brentuximab Vedotin (BV): Preliminary Analysis of the Believe Study (NCT:04998331)

Prospective Assessment of Motor Neurotoxicity and Sarcopenia in CD30+ Lymphoma Patients Treated with Brentuximab Vedotin. Single Center Multidisciplinary Unit Experience

Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only